Cancer, Non-small cell lung carcinoma
IMABI-MabCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Uliledlimab (TJD5) (TJ004309) +/- toripalimab & +/- pembrolizumab in Cancer, Non-small cell lung carcinoma. The expected timing is based on the latest available company guidance and may change.
04/07/26:- PR No update. 08/20/26:- PR No update.
Verification
Confirm timing and program details against the company announcement or filing.